Article

FDA seeks answers before approving drug

Irvine, CA-Allergan Inc. is continuing to evaluate a clinical study of its brimonidine tartrate/timolol maleate ophthalmic solution 0.2%/0.5% (Combigan) in an effort to address FDA questions prior to final marketing approval.

Irvine, CA-Allergan Inc. is continuing to evaluate a clinical study of its brimonidine tartrate/timolol maleate ophthalmic solution 0.2%/0.5% (Combigan) in an effort to address FDA questions prior to final marketing approval.

The company announced in late December that the FDA had issued an approvable letter for the drug, indicated to reduce elevated IOP in patients with glaucoma or ocular hypertension. An approvable letter outlines the remaining conditions a company must meet to obtain final FDA approval.

In its letter, the FDA suggested an additional confirmatory study to address certain questions. Allergan said it had begun that study in late 2005 and that it should address those questions.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) CCOI sets the stage for global ophthalmic innovation at Stanford Summit on July 23
(Image credit: Ophthalmology Times) Accelerating eye health innovation through CCOI – Stanford Summit
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game (Part 2)
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game? (Part 1)
© 2025 MJH Life Sciences

All rights reserved.